ITMI20020681A1 - Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina - Google Patents

Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Info

Publication number
ITMI20020681A1
ITMI20020681A1 IT2002MI000681A ITMI20020681A ITMI20020681A1 IT MI20020681 A1 ITMI20020681 A1 IT MI20020681A1 IT 2002MI000681 A IT2002MI000681 A IT 2002MI000681A IT MI20020681 A ITMI20020681 A IT MI20020681A IT MI20020681 A1 ITMI20020681 A1 IT MI20020681A1
Authority
IT
Italy
Prior art keywords
albumina
paclitaxel
nanoparticles
procedure
production
Prior art date
Application number
IT2002MI000681A
Other languages
English (en)
Inventor
Maurizio Zenoni
Simone Maschio
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITMI20020681A0 publication Critical patent/ITMI20020681A0/it
Priority to IT2002MI000681A priority Critical patent/ITMI20020681A1/it
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Priority to EP03004629A priority patent/EP1348431A1/en
Priority to AU2003200920A priority patent/AU2003200920A1/en
Priority to IL15476203A priority patent/IL154762A0/xx
Priority to NZ524605A priority patent/NZ524605A/en
Priority to US10/383,639 priority patent/US20030185894A1/en
Priority to ZA200302040A priority patent/ZA200302040B/xx
Priority to JP2003070028A priority patent/JP4794115B2/ja
Priority to MXPA03002543A priority patent/MXPA03002543A/es
Priority to BR0300846-0A priority patent/BR0300846A/pt
Priority to KR10-2003-0019242A priority patent/KR20030078722A/ko
Priority to CNB031083617A priority patent/CN1259902C/zh
Priority to CNA2006100770064A priority patent/CN1911446A/zh
Priority to RU2003108821/15A priority patent/RU2003108821A/ru
Priority to CA002423915A priority patent/CA2423915A1/en
Priority to NO20031448A priority patent/NO334407B1/no
Publication of ITMI20020681A1 publication Critical patent/ITMI20020681A1/it
Priority to US11/334,004 priority patent/US20060121119A1/en
Priority to JP2011043799A priority patent/JP2011132253A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
IT2002MI000681A 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina ITMI20020681A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP03004629A EP1348431A1 (en) 2002-03-29 2003-03-03 Process for producing nanoparticles of paclitaxel and albumin
AU2003200920A AU2003200920A1 (en) 2002-03-29 2003-03-05 Process for producing nanoparticles of paclitaxel and albumin
IL15476203A IL154762A0 (en) 2002-03-29 2003-03-05 Process for producing nanoparticles of paclitaxel and albumin
NZ524605A NZ524605A (en) 2002-03-29 2003-03-07 Process for producing nanoparticles of paclitaxel and albumin
US10/383,639 US20030185894A1 (en) 2002-03-29 2003-03-10 Process for producing nanoparticles of paclitaxel and albumin
ZA200302040A ZA200302040B (en) 2002-03-29 2003-03-13 Process for producing nanoparticles of paclitaxel and albumin.
JP2003070028A JP4794115B2 (ja) 2002-03-29 2003-03-14 パクリタキセルおよびアルブミンのナノ粒子を作製する方法
MXPA03002543A MXPA03002543A (es) 2002-03-29 2003-03-24 Proceso para producir nanoparticulas de paclitaxel y albumina.
BR0300846-0A BR0300846A (pt) 2002-03-29 2003-03-26 Processo para produzir nanopartìculas de paclitaxel e albumina
KR10-2003-0019242A KR20030078722A (ko) 2002-03-29 2003-03-27 파클리탁셀 및 알부민의 나노입자의 제조방법
CNB031083617A CN1259902C (zh) 2002-03-29 2003-03-28 制造紫杉醇和白蛋白的纳米颗粒的方法
CNA2006100770064A CN1911446A (zh) 2002-03-29 2003-03-28 制备紫杉醇和白蛋白的纳米颗粒的方法
RU2003108821/15A RU2003108821A (ru) 2002-03-29 2003-03-28 Способ получения наночастиц паклитаксела и альбумина
CA002423915A CA2423915A1 (en) 2002-03-29 2003-03-28 Process for producing nanoparticles of paclitaxel and albumin
NO20031448A NO334407B1 (no) 2002-03-29 2003-03-28 Fremgangsmåte for fremstilling av et sterilt, lyofilisert pulver bestående av nanopartikler av paclitaxel og humant serumalbumin
US11/334,004 US20060121119A1 (en) 2002-03-29 2006-01-17 Process for producing nanoparticles of paclitaxel and albumin
JP2011043799A JP2011132253A (ja) 2002-03-29 2011-03-01 パクリタキセルおよびアルブミンのナノ粒子を作製する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Publications (2)

Publication Number Publication Date
ITMI20020681A0 ITMI20020681A0 (it) 2002-03-29
ITMI20020681A1 true ITMI20020681A1 (it) 2003-09-29

Family

ID=11449619

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Country Status (15)

Country Link
US (2) US20030185894A1 (it)
EP (1) EP1348431A1 (it)
JP (2) JP4794115B2 (it)
KR (1) KR20030078722A (it)
CN (2) CN1911446A (it)
AU (1) AU2003200920A1 (it)
BR (1) BR0300846A (it)
CA (1) CA2423915A1 (it)
IL (1) IL154762A0 (it)
IT (1) ITMI20020681A1 (it)
MX (1) MXPA03002543A (it)
NO (1) NO334407B1 (it)
NZ (1) NZ524605A (it)
RU (1) RU2003108821A (it)
ZA (1) ZA200302040B (it)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1999000113A1 (en) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
DK1585548T3 (en) * 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20100278725A1 (en) * 2005-08-12 2010-11-04 Jiang Liu Methods and devices for lymphatic targeting
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP1870649A1 (en) 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2156823A1 (en) * 2008-08-14 2010-02-24 Pharmatex Italia Srl Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US20130058965A1 (en) * 2009-12-31 2013-03-07 Mannkind Corporation Injectable formulations for parenteral administration
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR100971087B1 (ko) * 2010-05-06 2010-07-16 김현수 불투명부에 암막기능을 갖는 블라인드지의 제직방법
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
CN102274190B (zh) * 2010-06-11 2012-12-05 上海现代药物制剂工程研究中心有限公司 一种注射用紫杉醇白蛋白亚微粒及其制备方法
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
JPWO2013137433A1 (ja) 2012-03-16 2015-08-03 大鵬薬品工業株式会社 ３剤を組み合わせた新規な抗腫瘍剤
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
CN105012251A (zh) * 2015-08-24 2015-11-04 吉林大学 注射用紫杉烷类药物白蛋白纳米粒冻干制剂及制备方法
AU2017324947A1 (en) * 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11617723B2 (en) 2016-09-27 2023-04-04 Sogang University Research Foundation Composition for hepatic arterial chemoembolization using human serum albumin nanoparticles carrying anticancer agent, and method for producing same
CN115487312B (zh) * 2016-10-27 2025-02-07 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
CN110496111B (zh) * 2018-05-18 2021-07-23 国家纳米科学中心 一种白蛋白纳米复合结构及其制备方法和应用
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
CN110585444A (zh) * 2019-10-31 2019-12-20 董军 一种中西医结合药物及其制备方法与应用
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
CN116942634A (zh) 2022-04-27 2023-10-27 石药集团中奇制药技术（石家庄）有限公司 一种速溶型纳米粒子组合物及其制备方法
EP4549859A1 (en) * 2022-06-28 2025-05-07 Compliance Consulting And Engineering Services, S.L. System for controlling the freeze-drying process in a freeze dryer with a plate stack system and a method for generating a design space
GB202401848D0 (en) 2024-02-11 2024-03-27 Univ College Dublin Nat Univ Ireland Dublin Albumin nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1999000113A1 (en) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
JP2002508758A (ja) * 1997-06-12 2002-03-19 エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー 生物的に活性な材料
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
CZ20023333A3 (cs) * 2000-04-10 2003-06-18 Teva Pharmaceutical Industries Ltd. Léčivo pro léčení rakoviny
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
RU2003108821A (ru) 2004-11-10
NZ524605A (en) 2004-03-26
CA2423915A1 (en) 2003-09-29
NO20031448L (no) 2003-09-30
BR0300846A (pt) 2004-08-17
CN1911446A (zh) 2007-02-14
ITMI20020681A0 (it) 2002-03-29
JP2011132253A (ja) 2011-07-07
IL154762A0 (en) 2003-10-31
NO20031448D0 (no) 2003-03-28
EP1348431A1 (en) 2003-10-01
JP2003300878A (ja) 2003-10-21
KR20030078722A (ko) 2003-10-08
CN1259902C (zh) 2006-06-21
JP4794115B2 (ja) 2011-10-19
US20030185894A1 (en) 2003-10-02
ZA200302040B (en) 2003-09-17
NO334407B1 (no) 2014-02-24
AU2003200920A1 (en) 2003-10-16
CN1448128A (zh) 2003-10-15
US20060121119A1 (en) 2006-06-08
MXPA03002543A (es) 2005-08-26

Similar Documents

Publication Publication Date Title
ITMI20020681A0 (it) Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CY2015015I1 (el) Παραγωγη τιακουμυκινης
DE60225385D1 (de) Autentisches Document und dessen Herstellungsverfahren
ITTO20030629A1 (it) Procedimento di realizzazione di collegamenti ad
DE60212628D1 (de) Nanopartikel-strukturen
PL1608811T3 (pl) Wyrób wielowarstwowy i sposób jego wytwarzania
ITPD20020316A1 (it) Dispositivo e metodo per la creazione di fullereni e/o nanotubi
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
ITUD20020222A1 (it) Procedimento per la produzione di manufatti poliuretanici e relativo dispositivo
GB0223149D0 (en) Nanoparticles
ITMI20022704A1 (it) Procedimento per la produzione di mesitilene e durene.
ITFI20010103A0 (it) Metodo ed attrezzatura per la produzione di mattonelle monostrato
GB2422378B (en) Fabrication of nanowires
ITBO20050705A1 (it) Macchina per la fabbricazione e l'erogazione di frappe' di gelato o schake
ITBO20030349A1 (it) Procedimento e macchina per la produzione di scatole di
DE602004006815D1 (de) Monolithischer Halbleiterlaser und dessen Herstellungsverfahren
DE602004005527D1 (de) Oberflächenemittierender Halbleiterlaser und dessen Herstellungsverfahren
ITMI20042139A1 (it) Procedimento per la produzione di cefepime e cefaposporine analoghe
ITMI20030811A1 (it) Procedimento ed impianto per la produzione di confezioni
ITMI20021739A1 (it) Procedimento ed apparecchiatura per la produzione di
ITMI20032105A1 (it) Procedimento e dispositivo per la produzione di parti
ITTO20030567A1 (it) Procedimento ed apparecchiatura per la produzione di un
ITBO20030267A1 (it) Metodo ed apparecchiatura per la realizzazione di articoli
ITTE20030003A1 (it) Procedimento per la realizzazione di stampi e/o matrici
ITMI20021429A1 (it) Procedimento per la realizzazione di piastrelle e piastrella ottenibile mediante tale procedimento